REDEFINE-3

randomised, double-blind, 2-armed, parallel-group, placebo-controlled trial primarily intended to assess the cardiovascular safety of CagriSema 2.4 mg/2.4 mg versus placebo, both administered subcutaneously (s.c.) once weekly in participants with obesity and established CVD